Clin2
NCT07766980Possibly a fitRecruiting

Nutritional supplement for quality of life in Duchenne muscular dystrophy

Duchenne Muscular DystrophyDuchenne DiseaseMuscular Dystrophy in ChildrenDMDMuscular Dystrophy

Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Infections clinical trials.

This study tests whether a daily nutritional supplement called VM100 can improve quality of life for people with Duchenne muscular dystrophy. If you are 8 or older and your medications have been stable for at least 3 months, you may be able to participate.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
20 people
Ages
6 years and older
Study type
Interventional

Who can take part

  • You have a confirmed diagnosis of Duchenne muscular dystrophy through genetic testing.
  • You are 8 years old or older.
  • Your steroid or other medication doses have been stable for at least 3 months and will stay the same during the study.
  • You do not have any other unstable medical conditions or illnesses that could interfere.
  • You do not have another condition affecting muscle function or metabolism (like myasthenia gravis, endocrine disorders, or mitochondrial disease).
  • You have not taken part in another experimental study in the last 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07058662Recruiting· Phase 1/Phase 2
Gene therapy study for Duchenne muscular dystrophy in boys 4-8

This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.

Beijing, Beijing Municipality
NCT03882827Recruiting
Natural history study of Duchenne muscular dystrophy in young boys

This study follows boys with Duchenne muscular dystrophy over time to better understand how the condition changes and how standard treatments affect health and function. It does not appear to test a new medicine, but it may help doctors plan better future care and studies.

Brussels
NCT07608432Recruiting· Phase 3
Testing a New DMD Treatment Given Every 4 Weeks

This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.

Hillsborough, North Carolina
NCT07287189Recruiting· Phase 2
SAT-3247 for boys with Duchenne muscular dystrophy

This trial tests a new daily pill called SAT-3247 for boys with Duchenne muscular dystrophy (DMD) who are still able to walk. The goal is to see if it can help slow muscle decline.

Los Angeles, California
NCT07704099Not yet recruiting· Phase 2
Study of KER-065 for Duchenne Muscular Dystrophy

This study tests a new medication called KER-065 to see if it helps people with Duchenne Muscular Dystrophy (DMD). It may help boys and men who are still walking, as well as those who use a wheelchair, as long as they are on a stable corticosteroid treatment.

NCT06692426Recruiting· Phase 1
Cell therapy for Duchenne muscular dystrophy

This trial tests a new cell-based treatment for Duchenne muscular dystrophy in adults who can no longer walk. The goal is to see if the therapy can help improve muscle function.

Minneapolis, Minnesota

Hear when a new Duchenne Muscular Dystrophy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.